A phase II study of paclitaxel/carboplatin plus bevacizumab/erlotinib in the first line treatment of patients with carcinoma of unknown primary site.

Trial Profile

A phase II study of paclitaxel/carboplatin plus bevacizumab/erlotinib in the first line treatment of patients with carcinoma of unknown primary site.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Erlotinib (Primary) ; Paclitaxel (Primary)
  • Indications Cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top